Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®

NCT06904820 | Recruiting

• 1 other identifier: 87RI24_0061 (SCANVIRE2)
• Study Type: observational
• Target: 2,300
• Locations: 1 country
• Sites: 1

Brief Summary

The "Scanvir" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a "test, treat and cure" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.

Conditions

Viral Hepatitis

Keywords

HCV; eradication; marginalized patients

Outcome Measures

Primary Outcomes (1)

• Evaluate the acceptability and the feasibility of simultaneous screening for viral hepatitis B, C and HIV among drug users and vulnerable populations in non-conventional structures using a triple method with RTD and FibroScan® and GeneXpert®.

  Feasibility will be assessed by the number of days and the number of participants in all sessions. the acceptability of TROD and/or Fibroscan will be assessed by the number and proportion of double screenings (TROD and/or Fibroscan) performed in relation to the number of screenings offered

  from enrollment to the end of the subject participation at the end of the day

Secondary Outcomes (8)

• Reinforce screening for hepatitis B (HBV), hepatitis Delta (HDV) and HIV,

  from enrollment to the end of the subject participation at the end of the day

• Reinforce education to prevent the risk of viral transmission,

  from enrollment to the end of the subject participation at the end of the day

• Encourage HBV vaccination,

  from enrollment to the end of the subject participation at the end of the day

• Evaluate the feasibility of PCR (GeneXpert/Buvard),

  from enrollment to the end of the subject participation at the end of the day

• Reinforce education to prevent the risk of viral transmission,

  from enrollment to the end of the subject participation at the end of the day

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

drug users and vulnerable populations in non-conventional structures

You may qualify if:

• Adult 18 and over
• Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
• Patient not opposed to research

You may not qualify if:

• Age under 18
• Patient opposed to research

Sponsors & Collaborators

• University Hospital, Limoges: lead

Study Sites (1)

Limoges University Hospital

Limoges, 87000, France

RECRUITING

Study Officials

• marilyne DEBETTE-GRATIEN, MD

  University Hospital, Limoges

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marilyne DEBETTE-GRATIEN, MD

CONTACT

+33555056604; marilyne.gratien@chu-limoges.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2025
• First Posted: April 1, 2025
• Study Start: June 5, 2025
• Primary Completion (Estimated): June 5, 2035
• Study Completion (Estimated): June 5, 2035
• Last Updated: August 14, 2025

Record last verified: 2025-02

Locations

FR (1)